

Received: October 29, 2020

ORIGINAL RESEARCH

**Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal  
Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra®) in the  
Republic of Korea, 2014–2019**

Hee Soo Kim • Solene Engel • David Neveu • Yael Thollot • Philipp Oster • Kuhyun Yang

H. S. Kim • K. Yang (✉)

Sanofi Pasteur, Seoul, Korea

e-mail: [shygh04@hotmail.com](mailto:shygh04@hotmail.com)

S. Engel

Sanofi Pasteur, Montpellier, France

D. Neveu

Sanofi Pasteur, Swiftwater, Pennsylvania, USA

Y. Thollot • P. Oster

Sanofi Pasteur, Lyon, France

## **ABSTRACT**

### **Background**

Invasive meningococcal disease is a notifiable disease in the Republic of Korea. The meningococcal (groups A, C, Y, and W) polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-DT, Menactra<sup>®</sup>) was licensed in the Republic of Korea in 2014. This post-marketing surveillance (PMS) observational study aims to assess the safety of MenACWY-DT administration of routine clinical care to individuals aged 9–23 months as a two-dose series at least 3 months apart and to individuals 2–55 years as a single dose.

### **Methods**

The PMS observational study (NCT02864927) included participants aged 9 months through 55 years and who were given MenACWY-DT during routine health-care visits. The study participants were followed-up for up to 30 days following vaccination (additional time was allowed for the visit or phone call to be conducted). Study outcomes included solicited and unsolicited adverse reactions, unexpected adverse events and serious adverse events (SAEs).

### **Results**

A total of 640 participants 9 through 23 months of age and 671 participants 2 through 55 years of age were eligible for safety analysis. Overall, AEs were reported by 35.3% of participants aged < 2 years and 45% of participants aged 2–55 years. Solicited adverse reactions were reported by 21.4% and 17.4% of participants aged < 2 years and 2–55 years, respectively. Unsolicited adverse reactions were reported by 26.1% and 37.9%, respectively. No vaccine-related SAEs occurred during the study. The AEs reported in Korean population

were consistent with the known safety profile of MenACWY-DT and most were of grade 1-2 in severity.

## **Conclusions**

This study did not detect any unanticipated or new safety findings of concern with MenACWY-DT in either of the study age groups and provides reassurance that MenACWY-DT can be used as part of routine immunization care for the prevention of invasive meningococcal disease.

**Trial Registration:** ClinicalTrials.gov Identifier, NCT02864927

**Keywords:** Adverse reactions or events; Menactra<sup>®</sup>; MenACWY-DT, MCV4; Meningococcal infections; Meningococcal vaccine; Safety; Vaccines

## **Key Summary Points**

- Post-marketing surveillance (PMS) of MenACWY-DT (Menactra<sup>®</sup>) provides the safety profile of this vaccine in a real-life setting.
- No safety concerns identified with MenACWY-DT in Korean population.
- MenACWY-DT is safe to use in children, adolescents and adults of age 9 months through 55 years.

## **DIGITAL FEATURES**

This article is published with digital features, including a summary slide, to facilitate understanding of the article. To view digital features for this article go to

<https://doi.org/10.6084/m9.figshare.13353113>

## INTRODUCTION

Meningococcal disease is caused by the gram-negative aerobic diplococcus *Neisseria meningitidis*. The serogroups A, B, C, W, and Y account for over 90% of meningococcal disease cases worldwide (1, 2). The prevalence of the meningococcal disease varies across different countries, ranging from 0.16–1.65 cases/100,000 individuals in well-developed countries to over 300 cases/100,000 individuals in the sub-Saharan meningitis belt (3). The greatest burden of meningococcal disease occurs in children under 5 years of age. The incidence peaks are also seen among adolescents and young adults (2, 4). According to global disability-adjusted life years (DALY) estimation, the burden of all-age meningitis (of all causes) was 20.4 million DALYs [17.8–23.4] in 2017 (5).

Invasive meningococcal disease (IMD) may present as acute sepsis or meningitis. Meningococcal meningitis combined with septic shock is responsible for a higher mortality (3). The burden of IMD in the Republic of Korea was reported to be relatively low with an annual incidence of 0.05 cases per 100,000 persons (6). High incidence rates were noted in Korean children < 5 years of age with approximately 1.35 cases per 100,000 persons (6). Serogroup B and C are the most common meningococcal carriage isolates among Korean adolescents; although serogroup distributions are consistently changing (7). There were outbreaks caused by serogroup W in 2011 in military recruits which led to required meningococcal vaccination of all recruits in 2012 (8). IMD remains an under-reported disease in Korea because of the limitations in culture surveillance methods and limited epidemiological studies (8-10). The lack of herd protection is also thought to be a risk factor for the outbreaks in the Republic of Korea (9). Vaccination is considered the best strategy to prevent IMD. Availability of novel vaccines including the meningococcal polysaccharide-conjugate vaccines to serogroups A, C, W, and Y (MenACWY), by conjugating the

polysaccharide antigen to a carrier protein, reduced the nasopharyngeal carriage and offered broader protection against a higher number of serogroups (2).

The meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra<sup>®</sup>) was approved by the U.S. Food and Drug Administration (FDA) in 2005 (11). Product license for Menactra<sup>®</sup> was approved in the Republic of Korea by Ministry of Food and Drug Safety (MFDS) in November 2014, for active immunization to prevent IMD caused by *Neisseria meningitidis* for individuals aged 11–55 years. Age indication was later expanded to include adults and children 9 months to 55 years of age in June 2015. Results from a randomized, phase 3 clinical trial in Korea confirmed that a single dose of MenACWY-DT induced an immune response with a seroconversion rate of > 60% for all four serogroups and was well-tolerated in Korean adolescents and adults (12). While several studies have investigated the safety of MenACWY-DT administered routinely to adolescents and adults (4, 13, 14), there are limited data on the safety of MenACWY-DT in Korean population. We monitored the safety of MenACWY-DT routinely administered in a post-licensure safety surveillance study across children 9–23-month-olds who are given a two series at least 3 months apart, and in adults and children aged 2–55 years when given as a single dose.

## **METHODS**

### **Study Design and Participants**

According to the MFDS regulations, an open, multi-center, prospective, observational study was performed within 4 years after the MenACWY-DT (Menactra<sup>®</sup>) product license approval in the Republic of Korea (ClinicalTrials.gov Identifier: NCT02864927) in children aged 9–23 months old across 25 institutions, from July 2016 to June 2019, and in population aged 2–55

years across 13 institutions from June 2016 to July 2018. The study protocol and amendments were approved by the institutional ethics committee or institutional review board (IRB) of Wonju Severance Christian Hospital. The IRB approval number for this study is CR115100-102. The study was performed according to local and national regulations and was consistent with the standards established by the Declaration of Helsinki and compliant with the International Council for Harmonization guidelines for Good Clinical Practice and MFDS regulations (basic standard for the re-examination of a new drug). An informed consent form was signed after vaccination by each participant, or participant's parents, or legally acceptable representatives before enrolment into the study.

Participants were enrolled after vaccination as per routine clinical practice. Children aged 9–23 months old who received two doses of MenACWY-DT at least 3 months apart were eligible. Participants 2–55-years of age who received one dose of MenACWY-DT during a routine healthcare visit were eligible. Enrolled subjects were followed after one dose of MenACWY-DT (first or second dose for subjects from 9 to 23 months) whatever their age was (and therefore vaccination schedule) at enrolment. The main exclusion criteria were previous (in the 4 weeks before enrolment) or planned participation in another clinical study.

### **Safety Evaluation**

Participants and/or caregivers were given a diary card to record safety information about daily temperature, daily measurement or intensity grade of all solicited injection site and systemic reactions, and the action taken to treat any solicited reactions, for the 7 days after vaccination (Day 0 to Day 7) until resolution. Information about any other medical events, including serious adverse events (SAEs), that may occur between the vaccination and the next visit and if any treatment provided was also recorded (Day 0 to Day 30). Unexpected adverse events (AEs) defined as an unsolicited AE, the nature or severity of which was not

consistent with the applicable product information (Korean product information leaflet), were also reported. The safety data was collected at visit 2 (30 [+7] days after visit 1 [day 0]). In case the participant could not attend visit 2, the safety information was obtained over telephone within 42 days from visit 1. Women participants who became pregnant during the study participation were asked to report their pregnancies. They were to be followed-up until the childbirth in order to obtain information about the outcome including spontaneous abortions, fetal death, stillbirth, and congenital anomalies if any reported.

### **Study Outcomes**

Primary endpoints included were the occurrence of solicited adverse reactions within 7 days of vaccination, unsolicited adverse events (spontaneously reported events) recorded for 30 days after vaccination, and SAEs occurring throughout the study.

The causality assessment between solicited reactions and serious/non-serious unsolicited systemic AEs and vaccination were assessed by the investigator as certain (a clinical event occurring in a plausible time relationship to drug administration), probable/likely (a clinical event with a reasonable time sequence to administration of the drug), possible (a clinical event with a reasonable time sequence to administration of the drug, but which could also be explained by concurrent disease or other drugs), unlikely (a clinical event with a temporal relationship to drug administration), conditional/unclassified (a clinical event for which more data is essential for a proper assessment), or unassessable/unclassified (an adverse reaction that cannot be judged because of insufficient information). The grades of severity included grade 1 (mild, regarded as having no interference with activity), grade 2 (moderate, regarded as having some interference with activity), and grade 3 (severe, regarded as significant and preventing daily activity). Safety analysis by subpopulations including gender, age, vaccination history (any vaccination within

the last 4 weeks), prior medical history (prior to enrolment, obtained verbally about the participant, with the help of parents in the case of children and adolescents), concomitant disease (any disease noted at the time of vaccine administration), and concomitant medication (any medication or vaccination being taken at the time of MenACWY-DT vaccination and during the course of the study) were performed.

## **Statistical Analyses**

No statistical hypotheses were tested, and all evaluations were descriptive in nature. A maximum of 1438 eligible/enrolled participants were planned to be recruited to ensure at least 600 evaluable participants were available in each age group (9–23 months and 2–55 years) for the safety assessments.

Safety analysis set included all those who received a dose of MenACWY-DT regardless of their vaccination schedule and were followed-up for safety evaluation. Safety surveillance in participants aged 9–23 months was considered only for one of the doses (1<sup>st</sup> or 2<sup>nd</sup> shot) administered. Summary statistics were presented for AEs (MedDRA preferred term [PT]), maximum intensity, action taken, time of onset, days of occurrence, and relationship to the vaccine. The 95% confidence intervals (CIs) were calculated using the exact binomial distribution according to the Clopper-Pearson's method for proportions and the normal approximation for quantitative data. All statistical analyses were carried out with SAS Software v.9.2 or above (Cary, NC, USA).

## **RESULTS**

Of the 648 (9–23 months of age) and 707 (2–55 years of age) participants enrolled, 640 (98.8%) and 671 (94.9%) were eligible for safety analysis. The main reasons for exclusion in both the age groups were lost to follow-up (5 and 23 participants, respectively) and not



meeting the inclusion criteria (2 participants in each). Demographics and baseline characteristics are presented in Table 1. Overall, AEs were reported by 35.3% of participants aged < 2 years and 45% of participants aged 2–55 years. Solicited adverse reactions were reported by 21.4% and 17.4% of participants aged < 2 years and 2–55 years, respectively. Unsolicited adverse reactions were reported by 26.1% and 37.9%, respectively. One participant reported one SAE during the follow-up period (Table 2). No women enrolled became pregnant during the study.

### **Solicited Adverse Reactions**

Solicited injection site reactions and systemic reactions were reported in 12.3% and 9.1% of participants < 2 years and 10.3% and 7.2% of participants aged 2–55 years, respectively. The most common solicited reactions in participants < 2 years were injection site erythema (7.2%) and pyrexia (4.4%) and in ages 2 through 55 years of age were injection site pain (9.2%) and myalgia (5.4%). Most solicited reactions began within 3 days post-vaccination, resolved within 1-3 days, and were grade 1 in intensity in both populations (Table 3). In participants aged < 2 years, for solicited reactions, comparison of the rates of injection site reactions/systemic reactions by prior vaccination versus no vaccination history was 22.1% versus 15.1% ( $P = 0.0414$ ). Comparison of rates in patients taking versus not taking concomitant medication/vaccinations was 21.3% versus 15.2% ( $P = 0.0440$ ). While for the 2–55 years age group, differences in the rates of injection site reactions/systemic reactions by age were 29.7% in participants aged  $\geq 20$  to < 30 years, 28.6% in  $\geq 40$  to  $\leq 55$  years aged and 21.7% in participants aged  $\geq 10$  to < 20 years ( $P = 0.0008$ ). Comparison of rates by prior vaccination versus no vaccination history was 4.1% versus 13.1% ( $P = 0.0248$ ), in patients with versus without past medical history include 60% versus 11.7% ( $P = 0.0142$ ), and in patients with versus without concomitant disease include 40% versus 11.4% ( $P = 0.0053$ ).

## Unsolicited Adverse Events

Unsolicited injection site reactions and systemic reactions were reported in 0.2% and 25.9% of participants < 2 years and 0.5% and 37.4% of participants aged 2–55 years, respectively.

The most commonly reported unsolicited injection site reactions were injection site induration, reported in 0.2% of participants aged < 2 years, and injection site pruritus, reported by 0.3% of participants aged 2–55 years. Nasopharyngitis was the most commonly reported unsolicited systemic event observed in both age groups (reported by 9.2% of participants < 2 years and 20.4% of participants 2–55 years) followed by bronchitis (reported by 5.3% of participants < 2 years and 5.1% of participants 2–55 years) and rhinitis (reported by 4.5% of participants < 2 years and 5.5% of participants 2–55 years). When assessed for causality, 25.8% and 0.3% were classified as unlikely (nasopharyngitis, 9.2%; bronchitis, 5.3%; rhinitis, 4.5%) and possible (rash, 0.2% and tonsillitis, 0.2%) unsolicited AEs, respectively, in age group < 2 years. The corresponding percentages in 2–55 years age group were 37.3% and 0.2%. None of the reported unsolicited systemic events were classified as certain, probable/likely, conditional/unclassified, or unassessable/unclassifiable in both the age groups. Most unsolicited AEs were of grade 1 in intensity (Table 4).

In participants < 2 years, the differences in the rates of unsolicited events by gender (male versus female) was 22.4% versus 30% ( $P = 0.0276$ ), by prior vaccination versus no vaccination history was 32.7% versus 22.5% ( $P = 0.0051$ ), with versus without concomitant disease was 47.6% versus 25.2% ( $P = 0.0212$ ), and comparison in patients taking versus not taking concomitant medication/vaccinations was 56% versus 3.0% ( $P < 0.0001$ ). Similarly, in participants 2–55 years, the rates of unsolicited events by age included 42.6% in participants aged  $\geq 2$  to < 10 years, 9.6% in  $\geq 10$  to  $\leq 20$  years and 12.5% in  $\geq 20$  to < 30 years of age ( $P < 0.0001$ ). Differences in the rates by prior vaccination versus no vaccination history was

58.1% versus 35.2% ( $P = 0.0001$ ), and comparison of patients taking versus not taking concomitant medications was 70.2% versus 2.5% ( $P < 0.0001$ ).

### **Unexpected Adverse Events**

The most frequently reported unexpected AEs in participants aged  $< 2$  years were nasopharyngitis (9.2%), bronchitis (5.3%) and rhinitis (4.5%), and in age group 2–55 years were nasopharyngitis (20.4%), rhinitis (5.5%) and bronchitis (5.1%). None of the AEs reported led to discontinuation of participants from either of the two groups. When the causal relationship between unexpected systemic events and vaccination was evaluated, most of the unexpected AEs were classified as unlikely ( $< 2$  years, 24.7%; 2–55 years, 36.7%). None of the unexpected systemic events were classified as certain, probable/likely, possible, conditional/unclassified, or unassessable/unclassifiable.

### **Adverse Events in Children and Adolescents**

The rate of any AEs among 604 children and adolescents aged 2–18 years was 46.9%. Solicited injection site reactions were reported by 9.5% and systemic events by 5.8%. The rate of unsolicited injection site reactions was 0.5% and that of unsolicited systemic events was 40.7%. Injection site pain (8.3%) and myalgia (4.6%) were the most common solicited AEs reported. Injection site pruritus (0.3%), nasopharyngitis (22.7%), rhinitis (6.1%), and bronchitis (5.6%) were the most common unsolicited AEs reported.

### **Serious Adverse Events**

Only one SAE, considered unrelated to vaccination, was reported during this study. A 15-month-old male was admitted to the hospital due to a common cold (nasopharyngitis) 20 days

after receiving the first dose of MenACWY-DT. This study participant was treated and recovered.

## **DISCUSSION**

This study evaluated the safety of MenACWY-DT in children 9–23 months of age, and older children, adolescents and adults aged 2–55 years. This is the first study to assess the safety of MenACWY-DT in the Republic of Korea after its approval in 2014 and in accordance with the MFDS regulations. The vaccine was well tolerated. There were no unanticipated or new safety findings of concern identified with MenACWY-DT in either of the study populations. Most of the local and systemic reactions were transient and of grades 1–2 in intensity. Nasopharyngitis, which was considered unrelated to vaccination and resolved upon treatment, was the only serious AE reported in a participant aged < 2 years old, while no serious AEs were reported among 2–55 years age group. No deaths occurred during the study, and no participants discontinued the study due to an AE or adverse reaction. Safety analysis by subpopulations showed differences which were statistically significant; however, they may not be clinically relevant considering the small sample size of the study population. The safety profile of MenACWY-DT in the subpopulation aged 2–18 years was generally comparable to the age group of 2–55 years.

The results reported were consistent with pre-licensure studies for the more common AEs, such as injection site and systemic reactions (12). The safety profile of MenACWY-DT appears to be similar to that observed in clinical studies and post-licensure studies undertaken in other regions (13–18). However, it should be noted that the results of this study represent lower rates of AEs compared to those reported in prospective randomized clinical trials.

Post-licensure vaccine safety surveillance is an essential component of any vaccination program and has important implications for informing national immunization policies. Although pre-licensure human clinical studies evaluate vaccine safety, these usually have a limited sample size, only assess otherwise healthy individuals. Therefore, rare AEs, and AEs only occurring in a unique sub-population may not be detected until a vaccine is widely used in the general population (19). A limitation of this study is the sample size, which is not large enough to detect extremely rare or uncommon events.

## **CONCLUSION**

In conclusion, the post marketing safety surveillance of the MenACWY-DT vaccine in the Korean population aged < 2 years and 2–55 years did not reveal any unexpected safety findings of concern. It reaffirms the safety of MenACWY-DT and provides reassurance for the use of the MenACWY-DT as part of routine immunization care for the prevention of meningococcal disease in the Republic of Korea.

## **ACKNOWLEDGEMENTS**

The authors would like to thank all participants who volunteered to take part in the study; the primary investigators and their site staff. We thank Roopsha Brahma, PhD, for editorial assistance and manuscript coordination on behalf of Sanofi Pasteur. Authors would like to also thank Seong Bin Lee the trial manager for the study.

## **Funding**

The study was funded by Sanofi Pasteur, Seoul, Korea. The Rapid Service Fee was funded by the sponsor, Sanofi Pasteur. All authors had full access to all of the data in this study as per

the local and national regulations and take complete responsibility for the integrity of the data and accuracy of the data analysis.

### **Medical Writing Assistance**

Medical writing support for this manuscript was provided by Rama Mylapuram, Pharm D (Sanofi) and funded by Sanofi Pasteur.

### **Authorship**

All named authors meet International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole and have given their approval for this version to be published.

### **Disclosures**

Hee Soo Kim, Solene Engel, David Neveu, Yael Thollot and Philipp Oster are employees of Sanofi. The current affiliation of Kuhyun Yang is Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangwon-do, Korea. Kuhyun Yang was an employee of Sanofi at the time of study.

### **Compliance with Ethics Guidelines**

The study protocol and amendments were approved by the institutional ethics committee or institutional review board (IRB) of Wonju Severance Christian Hospital. The IRB approval number for this study is CR115100-102. The study was performed according to local and national regulations and was consistent with the standards established by the Declaration of Helsinki and compliant with the International Council for Harmonization guidelines for Good Clinical Practice and MFDS regulations (basic standard for the re-examination of a new

drug). An informed consent form was signed after vaccination by each participant, or participant's parents, or legally acceptable representatives before enrolment into the study.

### **Data Availability**

The datasets generated during and/or analysed during the current study are not publicly available as the data sets are in Korean language but are available from the corresponding author on reasonable request.

## REFERENCES

1. Kang JH, Miao Y, Lee S, Kim JH, Lee KY, Ma SH, et al. A Survey of Serum Bactericidal Antibodies against *Neisseria meningitidis* Serogroups A, C, W and Y in Adolescents and Adults in the Republic of Korea. *Infect Chemother*. 2016;48(1):12-9.
2. Pizza M, Bekkat-Berkani R, Rappuoli R. Vaccines against Meningococcal Diseases. *Microorganisms*. 2020;8(10).
3. Lee H, Seo Y, Kim KH, Lee K, Choe KW. Prevalence and serogroup changes of *Neisseria meningitidis* in South Korea, 2010-2016. *Sci Rep*. 2018;8(1):5292.
4. Kim HW, Lee S, Lee JH, Woo SY, Kim KH. Comparison of Immune Responses to Two Quadrivalent Meningococcal Conjugate Vaccines (CRM197 and Diphtheria Toxoid) in Healthy Adults. *J Korean Med Sci*. 2019;34(23):e169.
5. DALYs GBD, Collaborators H, Murray CJ, Barber RM, Foreman KJ, Abbasoglu Ozgoren A, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. *Lancet*. 2015;386(10009):2145-91.
6. Aye AMM, Bai X, Borrow R, Bory S, Carlos J, Caugant DA, et al. Meningococcal disease surveillance in the Asia-Pacific region (2020): the Global Meningococcal Initiative. *Journal of Infection*. 2020.
7. Kim HW, Lee S, Kwon D, Cha J, Ahn JG, Kim KH. Characterization of Oropharyngeal Carriage Isolates of *Neisseria meningitidis* in Healthy Korean Adolescents in 2015. *J Korean Med Sci*. 2017;32(7):1111-7.
8. Heo JY. Meningococcal Disease in Korea: an Epidemiologic Study of the Underestimated Infectious Disease. *Infect Chemother*. 2016;48(1):51-3.
9. Borrow R, Lee JS, Vazquez JA, Enwere G, Taha MK, Kamiya H, et al. Meningococcal disease in the Asia-Pacific region: Findings and recommendations from the Global Meningococcal Initiative. *Vaccine*. 2016;34(48):5855-62.
10. Kim SA, Kim DW, Dong BQ, Kim JS, Anh DD, Kilgore PE. An expanded age range for meningococcal meningitis: molecular diagnostic evidence from population-based surveillance in Asia. *BMC Infect Dis*. 2012;12:310.
11. Menactra® Prescribing information. 2018. Available from: <https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Package-Insert---Menactra.pdf> Accessed on 28 July 2020.
12. Kim DS, Kim MJ, Cha SH, Kim HM, Kim JH, Kim KN, et al. Safety and immunogenicity of a single dose of a quadrivalent meningococcal conjugate vaccine (MenACYW-D): a multicenter, blind-observer, randomized, phase III clinical trial in the Republic of Korea. *Int J Infect Dis*. 2016;45:59-64.
13. Hansen J, Zhang L, Eaton A, Baxter R, Robertson CA, Decker MD, et al. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children. *Vaccine*. 2018;36(16):2133-8.
14. Hansen J, Zhang L, Klein NP, Robertson CA, Decker MD, Greenberg DP, et al. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine. *Vaccine*. 2017;35(49 Pt B):6879-84.
15. Fukushima S, Kikuchi H, Miyazu M, Hamada A, Ouchi K, Takagi H, et al. A Safety and Immunogenicity Study of a Single Dose of a Meningococcal (Groups A, C, W, and Y) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (MEN-ACWY-D) in Healthy Japanese Participants. *Jpn J Infect Dis*. 2018;71(6):402-7.
16. Javadekar B, Ghosh A, Kompithra RZ, Awasthi S, Perminova O, Romanenko V, et al. Safety and Immunogenicity of Two Doses of a Quadrivalent Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Indian and Russian Children Aged 9 to 17 Months. *Indian Pediatr*. 2018;55(12):1050-5.



17. Myers TR, McNeil MM, Ng CS, Li R, Marquez PL, Moro PL, et al. Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra(R)) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016. *Vaccine*. 2020;38(40):6291-8.
18. Robertson CA, Greenberg DP, Hedrick J, Pichichero M, Decker MD, Saunders M. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine. *Vaccine*. 2016;34(44):5273-8.
19. Li R, Weintraub E, McNeil MM, Kulldorff M, Lewis EM, Nelson J, et al. Meningococcal conjugate vaccine safety surveillance in the Vaccine Safety Datalink using a tree-temporal scan data mining method. *Pharmacoepidemiol Drug Saf*. 2018;27(4):391-7.

Pre-typeset version

## Tables and figures

**Table 1. Demographics of participants**

| Characteristic  | Participants aged 9–23 months (N = 640) | Participants aged 2–55 years (N = 671) |
|---|---|--|
| Gender  | 340 (53.1):300 (46.9)                   | 305 (45.5):366 (54.6)                  |
| Male, n (%): female, n (%)  |   |  |
| Age, median (range)   | 12 months (9-23)                        | 3 years (2-55)                         |
| Vaccination history within 4 weeks prior to the date of study vaccine administration, n (%) | 217 (33.9)                              | 74 (11)                                |
| Study vaccine administration  |   |  |
| Injection dose, n (%)   |   |  |
| 1 <sup>st</sup> dose  | 575 (89.8)                              | 670 (99.9)                             |
| 2 <sup>nd</sup> dose  | 65 (10.2)                               | 1 (0.2)                                |
| Injection side, n (%)   |   |  |
| Right   | 162 (25.3)                              | 93 (13.9)                              |
| Left  | 478 (74.7)                              | 578 (86.1)                             |
| Injection site, n (%)   |   |  |
| Upper arm   | 273 (42.7)                              | 621 (92.6)                             |
| Thigh   | 367 (57.3)                              | 50 (7.5)                               |
| Other   | 0                                       | 0                                      |

**Table 2. Overall incidence of adverse reactions and events reported**

|                          | Participants aged 9–23 months (N = 640) |               |           | Participants aged 2–55 years (N = 671) |               |           |
|--------------------------|---|---------------|-----------|--|---------------|-----------|
|                          | Participants with AEs, n (%)            | Number of AEs | 95% CI    | Participants with AEs, n (%)           | Number of AEs | 95% CI    |
| Solicited reactions      |   |               |           |  |               |           |
| Injection site reactions | 79 (12.3)                               | 111           | 9.9-15.2  | 69 (10.3)                              | 108           | 8.1-12.8  |
| Systemic reactions       | 58 (9.1)                                | 115           | 7-11.6    | 48 (7.2)                               | 86            | 5.3-9.4   |
| Unsolicited AEs          |   |               |           |  |               |           |
| Injection site           | 1 (0.2)                                 | 1             | 0-0.9     | 3 (0.5)                                | 3             | 0.1-1.3   |
| Systemic                 | 166 (25.9)                              | 311           | 22.6-29.5 | 251 (37.4)                             | 400           | 33.7-41.2 |
| Serious AEs              | 1 (0.2)                                 | 1             | -         | 0                                      | 0             | -         |

*AEs* adverse events; *CI* confidence interval

**Table 3. Overall incidence of solicited adverse reactions**

|                          | Participants aged 9–23 months (N = 640) |               |          |                |                |                | Participants aged 2–55 years (N = 671) |               |          |                |                |                |
|--------------------------|---|---------------|----------|----------------|----------------|----------------|--|---------------|----------|----------------|----------------|----------------|
|                          | Participants with ARs, n (%)            | Number of ARs | 95% CI   | Severity       |                |                | Participants with ARs, n (%)           | Number of ARs | 95% CI   | Severity       |                |                |
|                          |   |               |          | Grade 1, n (%) | Grade 2, n (%) | Grade 3, n (%) |  |               |          | Grade 1, n (%) | Grade 2, n (%) | Grade 3, n (%) |
| Injection site reactions | 79 (12.3)                               | 111           | 9.9-15.2 | 35 (5.5)       | 12 (1.9)       | 3 (0.5)        | 69 (10.3)                              | 108           | 8.1-12.8 | 59 (8.8)       | 16 (2.4)       | 10 (1.5)       |
| Injection site erythema  | 46 (7.2)                                | 46            | 5.3-9.5  | 12 (1.9)       | 7 (1.1)        | 3 (0.5)        | 22 (3.3)                               | 22            | 2.1-4.9  | 9 (1.3)        | 6 (0.9)        | 7 (1)          |
| Injection site pain      | 33 (5.2)                                | 33            | 3.6-7.2  | 24 (3.8)       | 8 (1.3)        | 0              | 62 (9.2)                               | 62            | 7.2-11.7 | 51 (7.6)       | 10 (1.5)       | 1 (0.2)        |
| Injection site swelling  | 32 (5)                                  | 32            | 3.4-7.0  | 10 (1.6)       | 3 (0.5)        | 1 (0.2)        | 24 (3.6)                               | 24            | 2.3-5.3  | 16 (2.4)       | 3 (0.5)        | 5 (0.8)        |
| Systemic reactions       | 58 (9.1)                                | 115           | 7.0-11.6 | 44 (6.9)       | 18 (2.8)       | 7 (1.1)        | 48 (7.2)                               | 86            | 5.3-9.4  | 38 (5.7)       | 13 (1.9)       | 3 (0.5)        |
| Crying                   | 14 (2.2)                                | 14            | 1.2-3.6  | 10 (1.6)       | 1 (0.2)        | 3 (0.5)        | -                                      | -             | -        | -              | -              | -              |
| Decreased appetite       | 24 (3.8)                                | 24            | 2.4-5.5  | 22 (3.4)       | 2 (0.3)        | 0              | -                                      | -             | -        | -              | -              | -              |
| Irritability             | 21 (3.3)                                | 21            | 2.0-5.0  | 10 (1.6)       | 8 (1.3)        | 3 (0.5)        | -                                      | -             | -        | -              | -              | -              |
| Pyrexia                  | 28 (4.4)                                | 28            | 2.9-6.3  | 15 (2.3)       | 7 (1.1)        | 1 (0.2)        | 7 (1)                                  | 7             | 0.4-2.1  | 4 (0.6)        | 1 (0.2)        | 1 (0.2)        |
| Somnolence               | 20 (3.1)                                | 20            | 1.9-4.8  | 14 (2.2)       | 4 (0.6)        | 2 (0.3)        | -                                      | -             | -        | -              | -              | -              |
| Vomiting                 | 8 (1.3)                                 | 8             | 0.5-2.5  | 4 (0.6)        | 2 (0.3)        | 2 (0.3)        | -                                      | -             | -        | -              | -              | -              |
| Headache                 | -                                       | -             | -        | -              | -              | -              | 18 (2.7)                               | 18            | 1.6-4.2  | 15 (2.2)       | 3 (0.5)        | 0              |
| Malaise                  | -                                       | -             | -        | -              | -              | -              | 25 (3.7)                               | 25            | 2.4-5.5  | 19 (2.8)       | 5 (0.8)        | 1 (0.2)        |
| Myalgia                  | -                                       | -             | -        | -              | -              | -              | 36 (5.4)                               | 36            | 3.8-7.4  | 26 (3.9)       | 7 (1)          | 3 (0.5)        |

ARs adverse reactions; CI confidence interval. Grade 1 (mild) regarded as having no interference with activity), grade 2 (moderate) regarded as having some interference with activity), and grade 3 (severe) regarded as significant and preventing daily activity.

**Table 4. Unsolicited adverse events which occurred with a frequency of at least 0.5% in either of the study participants**

|                                   | Participants aged 9–23 months (N = 640) |               |           | Participants aged 2–55 years (N = 671) |               |           |
|-----------------------------------|---|---------------|-----------|--|---------------|-----------|
|                                   | Participants with AEs, n (%)            | Number of AEs | 95% CI    | Participants with AEs, n (%)           | Number of AEs | 95% CI    |
| Injection site events             | 1 (0.2)                                 | 1             | 0-0.9     | 3 (0.5)                                | 3             | 0.1-1.3   |
| Systemic reactions                | 166 (25.9)                              | 311           | 22.6-29.5 | 251 (37.4)                             | 400           | 33.7-41.2 |
| Eye discharge                     | 3 (0.5)                                 | 3             | 0.1-1.4   | -                                      | -             | -         |
| Constipation                      | 2 (0.3)                                 | 2             | 0-1.1     | 5 (0.8)                                | 5             | 0.2-1.7   |
| Diarrhoea                         | 6 (0.9)                                 | 6             | 0.3-2     | 1 (0.2)                                | 1             | 0-0.8     |
| Enteritis                         | 6 (0.9)                                 | 6             | 0.3-2     | 10 (1.5)                               | 10            | 0.7-2.7   |
| Pyrexia                           | 11 (1.7)                                | 11            | 0.9-3.1   | 3 (0.5)                                | 3             | 0.1-1.3   |
| Bronchitis                        | 34 (5.3)                                | 36            | 3.7-7.3   | 34 (5.1)                               | 37            | 3.5-7     |
| Conjunctivitis                    | 4 (0.6)                                 | 4             | 0.2-1.6   | 5 (0.8)                                | 5             | 0.2-1.7   |
| Gastroenteritis                   | 6 (0.9)                                 | 6             | 0.3-2     | 3 (0.5)                                | 3             | 0.1-1.3   |
| Impetigo                          | 3 (0.5)                                 | 3             | 0.1-1.4   | 4 (0.6)                                | 4             | 0.2-1.5   |
| Influenza                         | 3 (0.5)                                 | 3             | 0.1-1.4   | -                                      | -             | -         |
| Nasopharyngitis                   | 59 (9.2)                                | 63            | 7.1-11.7  | 137 (20.4)                             | 147           | 17.4-23.7 |
| Otitis media                      | 11 (1.7)                                | 12            | 0.9-3.1   | 4 (0.6)                                | 4             | 0.2-1.5   |
| Pharyngitis                       | 5 (0.8)                                 | 6             | 0.3-1.8   | -                                      | -             | -         |
| Rhinitis                          | 29 (4.5)                                | 30            | 3.1-6.4   | 37 (5.5)                               | 47            | 3.9-7.5   |
| Sinusitis                         | 7 (1.1)                                 | 7             | 0.4-2.2   | 2 (0.3)                                | 3             | 0-1.1     |
| Tonsillitis                       | 6 (0.9)                                 | 6             | 0.3-2     | 2 (0.3)                                | 3             | 0-1.1     |
| Upper respiratory tract infection | 5 (0.8)                                 | 5             | 0.3-1.8   | -                                      | -             | -         |
| Arthropod bite                    | 3 (0.5)                                 | 3             | 0.1-1.4   | -                                      | -             | -         |
| Asthma                            | 5 (0.8)                                 | 5             | 0.3-1.8   | 4 (0.6)                                | 4             | 0.2-1.5   |
| Cough                             | 13 (2)                                  | 14            | 1.1-3.5   | 7 (1)                                  | 9             | 0.4-2.1   |
| Nasal congestion                  | 3 (0.5)                                 | 3             | 0.1-1.4   | 1 (0.2)                                | 1             | 0-0.8     |
| Productive cough                  | 4 (0.6)                                 | 4             | 0.2-1.6   | 2 (0.3)                                | 2             | 0-1.1     |
| Rhinitis allergic                 | 12 (1.9)                                | 12            | 1-3.3     | 11 (1.6)                               | 11            | 0.8-2.9   |
| Rhinorrhoea                       | 14 (2.2)                                | 15            | 1.2-3.6   | 9 (1.3)                                | 12            | 0.6-2.5   |
| Sneezing                          | 3 (0.5)                                 | 3             | 0.1-1.4   | 1 (0.2)                                | 1             | 0-0.8     |

|                                      | Participants aged 9–23 months (N = 640) |               |         | Participants aged 2–55 years (N = 671) |               |         |
|--------------------------------------|---|---------------|---------|--|---------------|---------|
|                                      | Participants with AEs, n (%)            | Number of AEs | 95% CI  | Participants with AEs, n (%)           | Number of AEs | 95% CI  |
| Upper respiratory tract inflammation | 6 (0.9)                                 | 6             | 0.3-2   | 32 (4.8)                               | 33            | 3.3-6.7 |
| Dermatitis atopic                    | 3 (0.5)                                 | 3             | 0.1-1.4 | -                                      | -             | -       |
| Dermatitis                           | 3 (0.5)                                 | 3             | 0.1-1.4 | -                                      | -             | -       |
| Dermatitis allergic                  | -                                       | -             | -       | 11 (1.6)                               | 11            | 0.8-2.9 |
| Rash                                 | 5 (0.8)                                 | 5             | 0.3-1.8 | 2 (0.3)                                | 2             | 0-1.1   |
| Urticaria                            | 3 (0.5)                                 | 3             | 0.1-1.4 | 4 (0.6)                                | 5             | 0.2-1.5 |

*AEs* adverse events